Advertisement

Topics

Pharmasset, Inc. Company Profile

23:22 EST 4th December 2016 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.

Location

303-A College Road East
Princeton
New Jersey
08540
United States of America

Contact

Phone: (609) 613-4100
Fax: (609) 613-4150
Email: info@pharmasset.com


News Articles [6 Associated News Articles listed on BioPortfolio]

Pharmasset, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

SummaryMarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an orga...

Is Gilead on the acquisition trail?

Speculation is mounting that Gilead could be on the acquisition trail after the company posted Q2 results showing sliding sales of its hepatitis C medicines, Sovaldi and Harvoni. Sales of the drugs, ...

U.S. Judge Frees Gilead from $200M in Damages to Merck

U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck used confidential information from Pharmasset

After “Hubris” and Its HCV Collapse, Can Vertex Avoid Same Mistakes?

Five years ago, in November 2011, a company from Princeton, NJ, called Pharmasset shared news that would have an impact on millions of people around the world with hepatitis C. Its experimental drug P...

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV.The exclu...

Judge overturns HCV patent ruling in Merck-Gilead case

A federal judge reversed a jury's decision in March that had upheld two HCV patents and had awarded $200 million in damages to Merck & Co. Inc. (NYSE:MRK) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...


Corporate Database Quicklinks



Searches Linking to this Company Record